BACKGROUND:Progestin contraception has been linked to higher risk of female to male sexual HIV transmission. SETTING: A clinical trial among HIV-infected women in Lilongwe, Malawi, randomized to initiation of depomedroxyprogesterone acetate injectable or levonorgestrel implant, and followed for up to 33 months, with the outcome of HIV shedding in the genital tract. METHODS: We compared the frequency and magnitude of HIV genital shedding before and after initiation of contraception and between study arms among women receiving antiretroviral therapy (ART). Genital HIV RNA was measured in TearFlo Strips using the Abbott RealTime HIV-1 assay. RESULTS: Among 68 HIV-infected Malawian women on ART, randomization to depot medroxyprogesterone acetate compared with the levonorgestrel implant was not associated with genital shedding and neither progestin contraceptive was associated with increased HIV genital shedding, for up to 33 months after contraceptive initiation. Having detectable plasma HIV [adjusted risk ratio (RR) 10.5; 95% confidence interval (CI): 3.18 to 34.7] and detectable genital shedding before contraceptive initiation (adjusted RR 3.53; 95% CI: 1.31 to 9.47) were associated with a higher risk of detectable genital shedding after contraceptive initiation. Higher plasma efavirenz concentrations were associated with a lower risk of detectable genital shedding (adjusted RR 0.85; 95% CI: 0.73 to 0.99, per increase of 1000 ng/mL). CONCLUSION: Among HIV-infected women receiving ART, our results provide evidence that progestin contraception does not impact women's risk of transmission of HIV to partners. Our finding that detectable genital shedding before contraceptive initiation independently predicts shedding suggests that there may be other individual-level biological or behavioral factors that increase the risk for shedding.
RCT Entities:
BACKGROUND: Progestin contraception has been linked to higher risk of female to male sexual HIV transmission. SETTING: A clinical trial among HIV-infectedwomen in Lilongwe, Malawi, randomized to initiation of depomedroxyprogesterone acetate injectable or levonorgestrel implant, and followed for up to 33 months, with the outcome of HIV shedding in the genital tract. METHODS: We compared the frequency and magnitude of HIV genital shedding before and after initiation of contraception and between study arms among women receiving antiretroviral therapy (ART). Genital HIV RNA was measured in TearFlo Strips using the Abbott RealTime HIV-1 assay. RESULTS: Among 68 HIV-infected Malawianwomen on ART, randomization to depot medroxyprogesterone acetate compared with the levonorgestrel implant was not associated with genital shedding and neither progestin contraceptive was associated with increased HIV genital shedding, for up to 33 months after contraceptive initiation. Having detectable plasma HIV [adjusted risk ratio (RR) 10.5; 95% confidence interval (CI): 3.18 to 34.7] and detectable genital shedding before contraceptive initiation (adjusted RR 3.53; 95% CI: 1.31 to 9.47) were associated with a higher risk of detectable genital shedding after contraceptive initiation. Higher plasma efavirenz concentrations were associated with a lower risk of detectable genital shedding (adjusted RR 0.85; 95% CI: 0.73 to 0.99, per increase of 1000 ng/mL). CONCLUSION: Among HIV-infectedwomen receiving ART, our results provide evidence that progestin contraception does not impact women's risk of transmission of HIV to partners. Our finding that detectable genital shedding before contraceptive initiation independently predicts shedding suggests that there may be other individual-level biological or behavioral factors that increase the risk for shedding.
Authors: T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray Journal: N Engl J Med Date: 2000-03-30 Impact factor: 91.245
Authors: Summer Day; Susan M Graham; Linnet N Masese; Barbra A Richardson; James N Kiarie; Walter Jaoko; Kishorchandra Mandaliya; Vrasha Chohan; Julie Overbaugh; R Scott McClelland Journal: J Acquir Immune Defic Syndr Date: 2014-08-01 Impact factor: 3.731
Authors: Athena P Kourtis; Lisa Haddad; Jennifer Tang; Lameck Chinula; Stacey Hurst; Jeffrey Wiener; Sascha Ellington; Julie A E Nelson; Amanda Corbett; Kristina De Paris; Caroline C King; Mina Hosseinipour; Irving F Hoffman; Denise J Jamieson Journal: Contemp Clin Trials Date: 2016-11-09 Impact factor: 2.226
Authors: Renee Heffron; Deborah Donnell; Helen Rees; Connie Celum; Nelly Mugo; Edwin Were; Guy de Bruyn; Edith Nakku-Joloba; Kenneth Ngure; James Kiarie; Robert W Coombs; Jared M Baeten Journal: Lancet Infect Dis Date: 2011-10-03 Impact factor: 25.071
Authors: Jared M Baeten; Erin Kahle; Jairam R Lingappa; Robert W Coombs; Sinead Delany-Moretlwe; Edith Nakku-Joloba; Nelly R Mugo; Anna Wald; Lawrence Corey; Deborah Donnell; Mary S Campbell; James I Mullins; Connie Celum Journal: Sci Transl Med Date: 2011-04-06 Impact factor: 17.956
Authors: Caroline C King; Sascha R Ellington; Nicole L Davis; Robert W Coombs; Maria Pyra; Ting Hong; Nelly Mugo; Rena C Patel; Jairam R Lingappa; Jared M Baeten; Athena P Kourtis Journal: J Infect Dis Date: 2017-12-19 Impact factor: 5.226
Authors: Clare Tanton; Helen A Weiss; Jerome Le Goff; John Changalucha; Mary Rusizoka; Kathy Baisley; Dean Everett; David A Ross; Laurent Belec; Richard J Hayes; Deborah Watson-Jones Journal: PLoS One Date: 2011-03-01 Impact factor: 3.240
Authors: Lameck Chinula; Julie A E Nelson; Jeffrey Wiener; Jennifer H Tang; Stacey Hurst; Gerald Tegha; Albans Msika; Sascha Ellington; Mina C Hosseinipour; Ronald Mataya; Lisa B Haddad; Athena P Kourtis Journal: Contraception Date: 2018-05-08 Impact factor: 3.375
Authors: Andrea J Low; Issouf Konate; Nicolas Nagot; Helen A Weiss; Dramane Kania; Peter Vickerman; Michel Segondy; David Mabey; Deenan Pillay; Nicolas Meda; Philippe van de Perre; Philippe Mayaud Journal: J Acquir Immune Defic Syndr Date: 2014-02-01 Impact factor: 3.731
Authors: Marta Bull; Caroline Mitchell; Jaime Soria; Sheila Styrchak; Corey Williams; Joan Dragavon; Kevin J Ryan; Edward Acosta; Frankline Onchiri; Robert W Coombs; Alberto La Rosa; Eduardo Ticona; Lisa M Frenkel Journal: J Infect Dis Date: 2020-08-04 Impact factor: 5.226